Re-evaluating disease-free survival (DFS) as an endpoint versus overall survival (OS) in adjuvant colon cancer (CC) trials with chemotherapy plus /- biologics: An updated surrogacy analysis based on 18,886 patients (pts) from the Accent database.

被引：4
|
作者：
Shi, Qian
De Gramont, Aimery
Dixon, Jesse G.
Yin, Jun
Van Cutsem, Eric
Taieb, Julien
Alberts, Steven R.
Wolmark, Norman
Schmoll, Hans-Joachim Hans-joachim
Saltz, Leonard B.
Goldberg, Richard M.
Kerr, Rachel
Lonardi, Sara
Yoshino, Takayuki
Yothers, Greg
Grothey, Axel
Andre, Thierry
Salem, Mohamed E.
机构：
[1] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA
[2] Franco British Inst, Dept Med Oncol, Levallois Perret, France
[3] Univ Hosp Gasthuisberg, Leuven, Belgium
[4] Katholieke Univ Leuven, Leuven, Belgium
[5] Paris Descartes Univ, Hop Europeen Georges Pompidou, Sorbonne Paris Cite, Paris, France
[6] Mayo Clin, Rochester, MN USA
[7] NRG Oncol, NSABP, Pittsburgh, PA USA
[8] Allegheny Gen Hosp, Allegheny Hlth Network Canc Inst, Pittsburgh, PA 15212 USA
[9] Halle Martin Luther Univ, Klin Innere Med 4, Univ Clin Halle Saale, Halle, Germany
[10] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[11] West Virginia Univ, Inst Canc, Morgantown, WV 26506 USA
[12] Univ Oxford, Oxford, England
[13] Ist Oncol Veneto IRCCS, Padua, Italy
[14] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[15] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA
[16] Univ Tennessee, West Canc Ctr, Germantown, TN USA
[17] Hop St Antoine, AP HP, Paris, France
[18] Sorbonne Univ, Paris, France
[19] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.3502
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3502
引用
收藏
页数：2
相关论文
共 15 条
  • [1] Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration.
    Sobrero, Alberto F.
    Andre, Thierry
    Meyerhardt, Jeffrey A.
    Grothey, Axel
    Iveson, Timothy
    Yoshino, Takayuki
    Sougklakos, Ioannis
    Meyers, Jeffrey P.
    Labianca, Roberto
    Saunders, Mark P.
    Vernerey, Dewi
    Yamanaka, Takeharu
    Boukovinas, Ioannis
    Oki, Eiji
    Georgoulias, Vassilis
    Torri, Valter
    Harkin, Andrea
    Taieb, Julien
    Shields, Anthony Frank
    Shi, Qian
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Individual patient data (IPD) analysis of progression-free survival (PFS) versus overall survival (OS) as an endpoint for metastatic colorectal cancer (mCRC) in modern trials: Findings from the 16,700 patients (pts) ARCAD database.
    Shi, Qian
    De Gramont, Aimery
    Buyse, Marc E.
    Grothey, Axel
    Schmoll, Hans-Joachim
    Seymour, Matthew T.
    Adams, Richard A.
    Saltz, Leonard
    Goldberg, Richard M.
    Punt, Cornelis J. A.
    Douillard, Jean-Yves
    Hecht, J. Randolph
    Hurwitz, Herbert
    Diaz-Rubio, Eduardo
    Porschen, Rainer
    Tebbutt, Niall C.
    Fuchs, Charles S.
    Souglakos, John
    Falcone, Alfredo
    Sargent, Daniel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Long term impact on disease-free survival (DFS) and overall survival (OS) of adjuvant anthracycline (AA) based chemotherapy (CT) in node positive (N plus ) breast cancer patients (PTS): A report of 258 pts with 20 years (Y) of follow-up (FU)
    不详
    BREAST, 2005, 14 : S35 - S35
  • [4] Disease-free survival (OFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials.
    Sargent, DJ
    Wieand, S
    Benedetti, J
    Labianca, R
    Haller, DG
    Shepherd, LE
    Seitz, JF
    Francini, G
    De Gramont, A
    Goldberg, RM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 245S - 245S
  • [5] Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials
    Sargent, DJ
    Wieand, HS
    Haller, DG
    Gray, R
    Benedetti, JK
    Buyse, M
    Labianca, R
    Seitz, JF
    O'Callaghan, CJ
    Francini, G
    Grothey, A
    O'Connell, M
    Catalano, PJ
    Blanke, CD
    Kerr, D
    Green, E
    Wolmark, N
    Andre, T
    Goldberg, RM
    De Gramont, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) : 8664 - 8670
  • [6] Population-based assessment of disease-free survival (DFS) as a surrogate endpoint (SE) of 5-year overall survival (5Y OS) in stage I-III rectal (RC) and colon cancer (CC).
    Lee-Ying, Richard M.
    Yin, Yaling
    Lim, Howard John
    Cheung, Winson Y.
    Kennecke, Hagen F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer A Secondary Analysis of the AVANT Trial
    Chibaudel, Benoist
    Henriques, Julie
    Rakez, Manel
    Brenner, Baruch
    Kim, Tae Won
    Martinez-Villacampa, Mercedes
    Gallego-Plazas, Javier
    Cervantes, Andres
    Shim, Katharine
    Jonker, Derek
    Guerin-Meyer, Veronique
    Mineur, Laurent
    Banzi, Chiara
    Dewdney, Alice
    Dejthevaporn, Thitiya
    Bloemendal, Haiko J.
    Roth, Arnaud
    Moehler, Markus
    Aranda, Enrique
    Van Cutsem, Eric
    Tabernero, Josep
    Schmoll, Hans-Joachim
    Hoff, Paulo M.
    Andre, Thierry
    de Gramont, Aimery
    JAMA NETWORK OPEN, 2020, 3 (10) : E2020425
  • [8] Prevalence, disease-free (DFS) and overall (OS) survival of contemporary high-risk renal cell carcinoma (RCC) patients eligible for adjuvant checkpoint inhibitor trials: A RECUR database analysis.
    Dabestani, Saeed
    Beisland, Christian
    Stewart, Grant
    Capitanio, Umberto
    Jarvinen, Petrus
    Nisen, Harry
    Bensalah, Karim
    Gudmundsson, Eirikur
    Lam, Thomas B.
    Marconi, Lorenzo
    Fernandez-Pello, Sergio
    Monagas, Serenella
    Powles, Thomas
    Meijer, Richard Paul
    Volpe, Alessandro
    Staehler, Michael D.
    Ljungberg, Borje
    Bex, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [9] Association between 3 year (yr) disease free survival (DFS) and overall survival (OS) delayed with improved survival after recurrence (REC) in patients receiving cytotoxic adjuvant therapy for colon cancer: Updated findings from the 20,800 patient (Pt) accent dataset
    Sargent, D.
    de Gramont, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 19 - 19
  • [10] Three-year disease-free survival (DFS) as surrogate end-point for predicting five-year overall survival (OS) benefit in adjuvant taxane-based chemotherapy for breast cancer (BC): Analysis of 10 randomized clinical trials (RCTs)
    Giannarelli, D.
    Bria, E.
    Cuppone, F.
    Ciccarese, M.
    Nistico, C.
    Carlini, P.
    Milella, M.
    Lorusso, V.
    Terzoli, E.
    Cognetti, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12